# 2026年1月27日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 接受左乙拉西坦单药治疗的儿童癫痫患者甲状腺功能与甲状腺体积评估

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41582223)
**期刊：** European journal of pediatrics
**PMID：** 41582223
**DOI：** 10.1007/s00431-026-06761-5

### 第一部分 原文与翻译

**英文原标题：** Evaluation of thyroid function and thyroid volume in pediatric epileptic patients receiving levetiracetam monotherapy.

> **英文摘要：**
> UNLABELLED: Epilepsy is a common neurological disorder in childhood, and levetiracetam, a newer anti-seizure medication (ASM), is widely used due to its efficacy and safety. Recent attention has focused on the effects of anti-seizure medication (ASM) on thyroid function. This study aimed to evaluate changes in thyroid function and thyroid volume in children receiving levetiracetam monotherapy. It is the first study to assess both thyroid function tests and ultrasonographic thyroid volume in this context. In this single-center, prospective study, 40 children aged 3 months to 18 years with epilepsy who began levetiracetam monotherapy at Dr. Behçet Uz Children's Hospital between January and June 2024 were included. Thyroid function tests (fT3, fT4, TSH, Anti-TPO, Anti-Tg) and thyroid volume (via ultrasound) were measured before treatment and at the 6th month, and analyzed using age-adjusted standard deviation scores (SDS). No statistically significant differences were found between baseline and 6th-month values for fT3 (p = 0.678), fT4 (p = 0.604), TSH (p = 0.210), Anti-TPO (p = 0.923), or Anti-Tg (p = 0.843). Thyroid volume showed no significant change (p = 0.159), but thyroid volume SDS decreased significantly (p = 0.018). CONCLUSION: Levetiracetam monotherapy over six months did not significantly affect thyroid hormone levels, autoantibodies, or absolute thyroid volume, although a decrease in thyroid volume SDS was noted. This may be due to measurement variability. Overall, short-term levetiracetam use appears safe in terms of thyroid function.

> **中文摘要：**
> 未分类：癫痫是童年时期常见的神经系统疾病，左乙拉西坦作为一种较新型的抗癫痫药物（ASM），因其疗效和安全性被广泛使用。近期研究的关注点集中在抗癫痫药物（ASM）对甲状腺功能的影响。本研究旨在评估接受左乙拉西坦单药治疗的儿童甲状腺功能和甲状腺体积的变化。这是首项在此背景下同时评估甲状腺功能测试和超声甲状腺体积的研究。在这项单中心前瞻性研究中，纳入了2024年1月至6月期间在Dr. Behçet Uz儿童医院开始接受左乙拉西坦单药治疗的40名3个月至18岁的癫痫患儿。在治疗前和第6个月分别测量了其甲状腺功能（fT3、fT4、TSH、抗TPO、抗Tg）和甲状腺体积（通过超声），并使用年龄校正的标准差评分（SDS）进行分析。结果显示，在fT3 (p = 0.678)、fT4 (p = 0.604)、TSH (p = 0.210)、抗TPO (p = 0.923) 或抗Tg (p = 0.843) 方面，基线值与第6个月的值之间均未发现统计学显著差异。甲状腺体积未见显著变化 (p = 0.159)，但甲状腺体积SDS显著下降 (p = 0.018)。结论：为期六个月的左乙拉西坦单药治疗未显著影响甲状腺激素水平、自身抗体或绝对甲状腺体积，尽管观察到甲状腺体积SDS有所下降。这可能是由于测量变异性所致。总体而言，短期使用左乙拉西坦在甲状腺功能方面表现安全。

### 第二部分 AI 大师评价

本研究是一项具有开拓意义的前瞻性临床观察，首次联合评估了左乙拉西坦对癫痫患儿甲状腺功能及超声体积的影响。研究结果明确指出，短期（6个月）左乙拉西坦单药治疗对甲状腺激素水平及自身抗体无显著干扰，证实了其良好的内分泌安全性。尽管发现甲状腺体积SDS有轻微统计学下降，但作者严谨地将其归因于测量变异而非药理损伤，为该药在儿科的临床应用提供了重要的循证依据。局限性在于样本量较小且随访时间有限，未来需更大规模研究探讨其长期效应。

---

速递结束，祝您工作愉快！